Benfluorex: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 27: Line 27:
{{CMG}}
{{CMG}}


{{Editor Join}}
 
==Overview==
==Overview==
'''Benfluorex''' is an [[anorectic]] and [[hypolipidemic agent]]. Clinical studies have shown it may improve [[glycemic control]] and decrease [[insulin resistance]] in people with poorly controlled [[diabetes mellitus type 2|type 2 diabetes]];<ref>{{cite journal |author=Moulin P, Andre M, Alawi H, ''et al'' |title=Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study |journal=Diabetes Care |volume=29 |issue=3 |pages=515–20 |year=2006 |pmid=16505498 |doi=}} [http://care.diabetesjournals.org/cgi/content/full/29/3/515 Free full text]</ref><ref>{{cite journal |author=Roger P, Auclair J, Drain P |title=Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo |journal=J Diabetes Complications |volume=13 |issue=2 |pages=62–7 |year=1999 |pmid=10432168 |doi=}}</ref> it is marketed in France as an adjuvant [[anti-diabetic drug|antidiabetic]].
'''Benfluorex''' is an [[anorectic]] and [[hypolipidemic agent]]. Clinical studies have shown it may improve [[glycemic control]] and decrease [[insulin resistance]] in people with poorly controlled [[diabetes mellitus type 2|type 2 diabetes]];<ref>{{cite journal |author=Moulin P, Andre M, Alawi H, ''et al'' |title=Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study |journal=Diabetes Care |volume=29 |issue=3 |pages=515–20 |year=2006 |pmid=16505498 |doi=}} [http://care.diabetesjournals.org/cgi/content/full/29/3/515 Free full text]</ref><ref>{{cite journal |author=Roger P, Auclair J, Drain P |title=Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo |journal=J Diabetes Complications |volume=13 |issue=2 |pages=62–7 |year=1999 |pmid=10432168 |doi=}}</ref> it is marketed in France as an adjuvant [[anti-diabetic drug|antidiabetic]].

Revision as of 22:50, 8 August 2012

Benfluorex
Clinical data
Routes of
administration		Oral
ATC code
Pharmacokinetic data
ExcretionRenal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H20F3NO2
Molar mass351.363 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Benfluorex is an anorectic and hypolipidemic agent. Clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes;[1][2] it is marketed in France as an adjuvant antidiabetic.

Benfluorex is structurally related to fenfluramine.

Benfluorex has been baned in France and the European Union because of links to thickening of heart valves and heart attacks.

  1. ↑ Moulin P, Andre M, Alawi H; et al. (2006). "Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study". Diabetes Care. 29 (3): 515–20. PMID 16505498. Free full text
  2. ↑ Roger P, Auclair J, Drain P (1999). "Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo". J Diabetes Complications. 13 (2): 62–7. PMID 10432168.
Retrieved from "https://www.wikidoc.org/index.php?title=Benfluorex&oldid=669657"